Will Brivaracetam Help My Patient? Only Time Will Tell

Jacqueline French. Epilepsy Curr. 2017 Jan-Feb.

. 2017 Jan-Feb;17(1):35-36.

doi: 10.5698/1535-7511-17.1.35.

No abstract available

Conflict of interest statement

Editor's Note: Authors have a Conflict of Interest disclosure which is posted under the Supplemental Materials link.

Letter re: Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.
Klein P, Benbadis SR, Diaz A, Moseley BD, Ben-Menachem E. Klein P, et al. Neurology. 2017 Oct 17;89(16):1756. doi: 10.1212/WNL.0000000000004512. Neurology. 2017. PMID: 29038138 No abstract available.

1. Klitgaard H, Matagne A, Nicolas JM, Gillard M, Lamberty Y, De Ryck M, Kaminski RM, Leclercq K, Niespodziany I, Wolff C, Wood M, Hannestad J, Kervyn S, Kenda B.. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. Epilepsia 2016; 57: 538– 548. - PubMed
1. Brigo F, Bragazzi NL, Nardone R, Trinka E.. Efficacy and tolerability of brivaracetam compared to lacosamide, eslicarbazepine acetate, and perampanel as adjunctive treatments in uncontrolled focal epilepsy: Results of an indirect comparison meta-analysis of RCTs. Seizure 2016; 42: 29– 37. - PubMed
1. Betts T, Waegemans T, Crawford P.. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 2000; 9: 80– 87. - PubMed
1. Klein P, Tyrlikova I, Brazdil M, Rektor I.. Brivaracetam for the treatment of epilepsy. Expert Opin Pharmacother 2016; 17: 283– 295. - PubMed
1. Full Briviact™ prescribing information. Center for Drug Evaluation and Research; http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205836Orig1s000_2.... Accessed October 23, 2016.